
|Articles|April 8, 2019 (Updated: December 19, 2020)
Osimertinib Plus Savolitinib Shows Activity in EGFR-Mutant, MET-Amplified NSCLC
Author(s)Lecia V. Sequist, MD, MPH
Cancer Network spoke with Lecia V. Sequist, MD, MPH, about the TATTON study, which tested the combination of osimertinib and savolitinib in previously treated non–small-cell lung cancer patients.
Advertisement
Cancer Network spoke with Lecia V. Sequist, MD, MPH, about the TATTON study, which tested the combination of osimertinib and savolitinib in previously treated non–small-cell lung cancer patients.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Related Content
Advertisement




Evaluating the Cost-Effectiveness of Immunotherapy in Lung Cancers
Published: | Updated:

Optimizing the Use of Hypofractionated Radiotherapy in Lung Cancer Care
Published: | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Grants Approval to Teclistamab Combo in RRMM
2
The Evolving Landscape of Immunotherapy in Breast Cancer
3
Cadonilimab Yields 100% 24-Month OS in Recurrent Cervical Cancer Population
4
New Zenocutuzumab Findings Provide Hope for Targeting Rare NSCLC Subtypes
5


















































